Cefuroxime Sodium

證據等級: L5

預測適應症: 0 個

CEFUROXIME SODIUM: Repurposing Evaluation — Insufficient Data for Full Assessment

One-Sentence Summary

Cefuroxime Sodium is a second-generation cephalosporin antibiotic used broadly to treat bacterial infections. The current Evidence Pack contains no TxGNN-predicted repurposing indications, and critical data — including SAHPRA registration records, mechanism of action, and safety warnings — are absent. A complete repurposing evaluation cannot be conducted until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Bacterial infections (second-generation cephalosporin; no SAHPRA-approved indication on file)
Predicted New Indication	None generated by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 — model produced no prediction for this drug
South Africa Market Status	Not Marketed (no SAHPRA registrations found)
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN pipeline returned an empty predicted indications list for Cefuroxime Sodium. Two factors likely contributed:

1. DrugBank ID not resolved. The query log confirms a successful DrugBank lookup (result count: 1), yet the drugbank_id field was not captured in the Evidence Pack. Without a confirmed DrugBank ID, the knowledge graph cannot anchor this drug to its node in the TxGNN graph, blocking prediction generation.

2. Missing original indication data. The original_indications array is empty. TxGNN uses the drug’s known disease associations as seed edges for repurposing inference; with no seed edges present, the model cannot traverse the graph to candidate diseases.

Currently, detailed mechanism of action data is not available. Based on general pharmacological knowledge, Cefuroxime Sodium inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Whether this mechanism has any relevance to a non-infectious repurposing indication remains entirely unassessed and cannot be commented on without a valid TxGNN prediction.

South Africa Market Information

No SAHPRA-registered products were identified for Cefuroxime Sodium in this Evidence Pack.

Note for reviewers: Cefuroxime is a widely used antibiotic globally and is included on the WHO Essential Medicines List. The absence of SAHPRA records most likely reflects a data extraction or name-matching failure (e.g., the active pharmaceutical ingredient may be registered under a salt/ester variant such as “Cefuroxime Axetil” or under brand names). Manual verification against the SAHPRA online register is recommended before concluding the drug is absent from the South African market.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety online portal.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack produced zero TxGNN repurposing candidates, and two blocking data gaps (missing DrugBank ID and missing original indication records) prevent the prediction pipeline from running correctly. No evidence-based repurposing evaluation can be completed in the current state.

To proceed, the following is needed:

[Critical] Resolve DrugBank ID: The DrugBank query returned one result but failed to capture the ID. Manually confirm the correct DrugBank entry (likely DB00514 for Cefuroxime) and re-run the mapping step.
[Critical] Re-run TxGNN pipeline after DrugBank ID is confirmed and original indications are populated (e.g., “bacterial infection”, “pneumonia”, “urinary tract infection”).
[Critical] Retrieve SAHPRA registration records by searching variant names: Cefuroxime Axetil, Cefuroxime Sodium, and common brand names (e.g., Zinnat, Zinacef).
[High] Download and parse the SAHPRA-approved Professional Information (PI) document to populate key warnings and contraindications (Data Gap DG001).
[High] Retrieve mechanism of action details from the DrugBank API once the DrugBank ID is confirmed (Data Gap DG002).
[Standard] Once a predicted indication is available, re-run the evidence collector to retrieve relevant clinical trials (ClinicalTrials.gov, PACTR, SANCTR) and PubMed literature.

This report was generated on 2026-04-05. All findings are for research purposes only and do not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. Adverse events should be reported to SAHPRA.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.